Targeted and armed oncolytic adenovirus via chemoselective modification

Partha S. Banerjee, Edison S. Zuniga, Iwao Ojima, Isaac S. Carrico

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Oncolytic adenoviruses (Ads) are an emerging alternative therapy for cancer; however, clinical trial have not yet demonstrated sufficient efficacy. When oncolytic Ads are used in combination with taxoids a synergistic increase in both cytotoxicity and viral replication is observed. In order to generate a next generation oncolytic adenovirus, virion were physically conjugated to a highly potent taxoid, SB-T-1214, and a folate targeting motif. Conjugation was enabled via the metabolic incorporation of non-canonical monosaccharides (O-GlcNAz) and amino acids (homopropargylglycine), which served as sites for chemoselective modification.

Original languageEnglish (US)
Pages (from-to)4985-4988
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Issue number17
StatePublished - Sep 1 2011
Externally publishedYes


  • Adenovirus
  • Chemoselective
  • Click
  • Gene delivery
  • Non-canonical
  • Oncolytic
  • Paclitaxel
  • Staudinger
  • Taxoid
  • Unnatural

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Targeted and armed oncolytic adenovirus via chemoselective modification'. Together they form a unique fingerprint.

Cite this